Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation
- PMID: 18796625
- DOI: 10.1182/blood-2008-06-161919
Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation
Abstract
Various human disorders are associated with misdistribution of iron within or across cells. Friedreich ataxia (FRDA), a deficiency in the mitochondrial iron-chaperone frataxin, results in defective use of iron and its misdistribution between mitochondria and cytosol. We assessed the possibility of functionally correcting the cellular properties affected by frataxin deficiency with a siderophore capable of relocating iron and facilitating its metabolic use. Adding the chelator deferiprone at clinical concentrations to inducibly frataxin-deficient HEK-293 cells resulted in chelation of mitochondrial labile iron involved in oxidative stress and in reactivation of iron-depleted aconitase. These led to (1) restoration of impaired mitochondrial membrane and redox potentials, (2) increased adenosine triphosphate production and oxygen consumption, and (3) attenuation of mitochondrial DNA damage and reversal of hypersensitivity to staurosporine-induced apoptosis. Permeant chelators of higher affinity than deferiprone were not as efficient in restoring affected functions. Thus, although iron chelation might protect cells from iron toxicity, rendering the chelated iron bioavailable might underlie the capacity of deferiprone to restore cell functions affected by frataxin deficiency, as also observed in FRDA patients. The siderophore-like properties of deferiprone provide a rational basis for treating diseases of iron misdistribution, such as FRDA, anemia of chronic disease, and X-linked sideroblastic anemia with ataxia.
Similar articles
-
Iron redistribution as a therapeutic strategy for treating diseases of localized iron accumulation.Can J Physiol Pharmacol. 2010 Mar;88(3):187-96. doi: 10.1139/Y09-128. Can J Physiol Pharmacol. 2010. PMID: 20393584 Review.
-
Deferiprone targets aconitase: implication for Friedreich's ataxia treatment.BMC Neurol. 2008 Jun 16;8:20. doi: 10.1186/1471-2377-8-20. BMC Neurol. 2008. PMID: 18558000 Free PMC article.
-
Deferiprone and idebenone rescue frataxin depletion phenotypes in a Drosophila model of Friedreich's ataxia.Gene. 2013 Jun 1;521(2):274-81. doi: 10.1016/j.gene.2013.02.049. Epub 2013 Mar 28. Gene. 2013. PMID: 23542074
-
Efficient attenuation of Friedreich's ataxia (FRDA) cardiomyopathy by modulation of iron homeostasis-human induced pluripotent stem cell (hiPSC) as a drug screening platform for FRDA.Int J Cardiol. 2016 Jan 15;203:964-71. doi: 10.1016/j.ijcard.2015.11.101. Epub 2015 Nov 17. Int J Cardiol. 2016. PMID: 26625322
-
Deferiprone for the treatment of Friedreich's ataxia.J Neurochem. 2013 Aug;126 Suppl 1:142-6. doi: 10.1111/jnc.12300. J Neurochem. 2013. PMID: 23859349 Review.
Cited by
-
Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy.J Cardiovasc Magn Reson. 2013 Jan 16;15(1):1. doi: 10.1186/1532-429X-15-1. J Cardiovasc Magn Reson. 2013. PMID: 23324167 Free PMC article.
-
Human iron-sulfur cluster assembly, cellular iron homeostasis, and disease.Biochemistry. 2010 Jun 22;49(24):4945-56. doi: 10.1021/bi1004798. Biochemistry. 2010. PMID: 20481466 Free PMC article. Review.
-
Pharmacological treatments for Friedreich ataxia.Cochrane Database Syst Rev. 2016 Aug 30;2016(8):CD007791. doi: 10.1002/14651858.CD007791.pub4. Cochrane Database Syst Rev. 2016. PMID: 27572719 Free PMC article. Review.
-
Current and emerging treatment options in the management of Friedreich ataxia.Neuropsychiatr Dis Treat. 2010 Sep 7;6:491-9. doi: 10.2147/ndt.s6916. Neuropsychiatr Dis Treat. 2010. PMID: 20856912 Free PMC article.
-
On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure.J Cardiovasc Magn Reson. 2011 Sep 12;13(1):45. doi: 10.1186/1532-429X-13-45. J Cardiovasc Magn Reson. 2011. PMID: 21910880 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous